A Bayesian dose-finding design for drug combination trials with delayed toxicities
From MaRDI portal
(Redirected from Publication:908029)
Sampling theory, sample surveys (62D05) Bayesian inference (62F15) Robustness and adaptive procedures (parametric inference) (62F35) Optimal statistical designs (62K05) Sequential statistical design (62L05) Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)
Recommendations
- Bayesian Dose-Finding in Phase I/II Clinical Trials Using Toxicity and Efficacy Odds Ratios
- Bayesian dose-finding in two treatment cycles based on the joint utility of efficacy and toxicity
- Adaptive Bayesian compound designs for dose finding studies
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Bayesian design for clinical trials with a constraint on the total available dose
- Bayesian phase II adaptive randomization by jointly modeling time-to-event efficacy and binary toxicity
- scientific article; zbMATH DE number 1154647
Cited in
(13)- Adaptive designs for drug combination informed by longitudinal model for the response
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Bayesian dose finding for combined drugs with discrete and continuous doses
- Constructing Release Targets for Drug Products: A Bayesian Decision Theory Approach
- Application of gamma process to two-agent combinations with delayed toxicity
- Bootstrap aggregating continual reassessment method for dose finding in drug-combination trials
- A combined proof of concept and dose finding study with multiple endpoints: A Bayesian adaptive design in chronic prostatitis/chronic pelvic pain syndrome
- Implementation of a Bayesian Design in a Dose‐Escalation Study of an Experimental Agent in Healthy Volunteers
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- Flexible use of copula‐type model for dose‐finding in drug combination clinical trials
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information
- Evaluation of phase I clinical trial designs for combinational agents along with guidance based on simulation studies
- Statistical frameworks for oncology dose-finding designs with late-onset toxicities: a review
This page was built for publication: A Bayesian dose-finding design for drug combination trials with delayed toxicities
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q908029)
